Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Eye Care

Journal Scan / Research · March 08, 2022

Proptosis and Diplopia Response With Teprotumumab and Placebo vs IV Methylprednisolone in Thyroid Eye Disease

JAMA Ophthalmology


Additional Info

JAMA Ophthalmology
Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison
JAMA Ophthalmol 2022 Feb 17;[EPub Ahead of Print], RS Douglas, R Dailey, PS Subramanian, G Barbesino, S Ugradar, R Batten, RA Qadeer, C Cameron

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading